These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12927658)

  • 1. Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP).
    Salomé HJ; French MT; Miller M; McLellan AT
    Drug Alcohol Depend; 2003 Aug; 71(2):195-206. PubMed ID: 12927658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of treating addiction from the client's perspective: results from a multi-modality application of the Client DATCAP.
    McCollister KE; French MT; Pyne JM; Booth B; Rapp R; Carr C
    Drug Alcohol Depend; 2009 Oct; 104(3):241-8. PubMed ID: 19574000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost estimation when time and resources are limited: the Brief DATCAP.
    French MT; Roebuck MC; McLellan AT
    J Subst Abuse Treat; 2004 Oct; 27(3):187-93. PubMed ID: 15501371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP).
    French MT; Dunlap LJ; Zarkin GA; McGeary KA; McLellan AT
    J Subst Abuse Treat; 1997; 14(5):445-55. PubMed ID: 9437614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the economic cost of substance abuse treatment.
    French MT; McGeary KA
    Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?
    Ettner SL; Huang D; Evans E; Ash DR; Hardy M; Jourabchi M; Hser YI
    Health Serv Res; 2006 Feb; 41(1):192-213. PubMed ID: 16430607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program.
    Roebuck MC; French MT; McLellan AT
    J Subst Abuse Treat; 2003 Jul; 25(1):51-7. PubMed ID: 14512108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Cost Analysis Tool (TCAT) for estimating costs of outpatient treatment services.
    Flynn PM; Broome KM; Beaston-Blaakman A; Knight DK; Horgan CM; Shepard DS
    Drug Alcohol Depend; 2009 Feb; 100(1-2):47-53. PubMed ID: 19004576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Service-level costing of drug abuse treatment.
    Anderson DW; Bowland BJ; Cartwright WS; Bassin G
    J Subst Abuse Treat; 1998; 15(3):201-11. PubMed ID: 9633032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costing substance misuse services.
    Coyle D; Godfrey C; Hardman G; Raistrick D
    Addiction; 1997 Aug; 92(8):1007-15. PubMed ID: 9376770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of substance abuse treatment modality on birth weight and health care expenditures.
    Daley M; Argeriou M; McCarty D; Callahan JJ; Shepard DS; Williams CN
    J Psychoactive Drugs; 2001; 33(1):57-66. PubMed ID: 11333002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment program operations and costs.
    Broome KM; Knight DK; Joe GW; Flynn PM
    J Subst Abuse Treat; 2012 Mar; 42(2):125-33. PubMed ID: 22154033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using cost and financing instruments for economic evaluation of substance abuse treatment services.
    Salomé HJ; French MT
    Recent Dev Alcohol; 2001; 15():253-69. PubMed ID: 11449745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the Treatment Services Review be used to estimate the costs of addiction and ancillary services?
    French MT; Roebuck MC; McLellan AT; Sindelar JL
    J Subst Abuse; 2000; 12(4):341-61. PubMed ID: 11452838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Client outcomes from rural substance abuse treatment.
    Hiller ML; Leukefeld CG; Garrity TF; Godlaski T; Schoeneberger M; Townsend M; Hascal K
    J Psychoactive Drugs; 2007 Mar; 39(1):59-68. PubMed ID: 17523586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
    Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
    J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.